| 영문 | agonist | 한글 | 작용제, 작용근 |
|---|---|---|---|
| 설명 | 1. 수용체와 결합하여 최대의 약리작용을 발현하는 화학물질을 말한다. 수용체에 특이하게 친화성을 가지고 있다. 생체 안에서 생산되는 내인성인 것과 생체 밖에서 투여되는 외인성인 것이 있다. 부분 작용제는 수용체와 결합해도 100%의 약리작용을 발현하지는 않으며 용량을 증가시켜도 효과는 커지지 않는다. 2. 해부학에서는 주가 되어 움직이는 근육의 무리 |
||
| 영문 | beta human chorionic gonadotropin | 한글 | 베타 사람융모성 생식샘자극호르몬 |
|---|---|---|---|
| 설명 | 태반세포에서 만들어지는 호르몬. 기능은 임신의 초기에 황체(원래 난자를 싸고 있던 세포들이 배란이 일어나서 난자가 빠져나간 후 주머니 모양을 이룬 것. 임신초기에 임신의 유지에 필요한 호르몬을 생성한다)의 유지에 기여하고, 태아의 고환조직에서 남성호르몬이 분비되는 것을 촉진시킨다. 또 이것은 임신초기의 임산부의 소변에서 많은 양이 검출되므로 이것을 이용해서 임신의 여부를 손쉽게 조사할 수가 있다. |
||
| 영문 | beta ray | 한글 | 베타선 |
|---|---|---|---|
| 설명 | 방사성 원자핵이 β붕괴함에 따라 방출되는 방사선. 원자에 정상보다 많거나 적은 중성자나 양자를 가지고 있는 경우에는 원자가 안정되기 위하여 붕괴가 세가지 방법으로 생긴다. 이중 중성자가 하나의 전자를 내고 양성자가 되는 변화를 거치면서 나오는 전자선이다. 그 실체는 고속의 전자 또는 양전자이며 최대 에너지는 105-107eV. 투과력 및 이온화 작용은 α선과 γ선의 중간 정도이다. |
||
| 영문 | beta-blocker | 한글 | 베타차단제 |
|---|---|---|---|
| 설명 | 베타-수용체(1과 2에 관계없이)의 기능을 억제시키는 약물로 이 수용체가 매개하여 생기는 신체의 변화를 억제한다. Propranolol이 좋은 예이다. |
||
| IHSS(= HCMP) | Idiopathic Hypertrophic Subaortic Stenosis = Obstructive Idiopathic Hypertrophic Car... |
|---|---|
| ORA | opiate receptor agonist |
| PAA | partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas... |
| BB | bad breath; bed bath; beta blockade, beta blocker; BioBreeding [rat]; blanket bath; blood bank; bloo... |
| beta [Greek letter beta] | an anomer of a carbohydrate; buffer capacity; carbon separated from a carboxyl by one other carbon i... |
| R,S | receptor agonist |
|---|---|
| 8-OH-DPAT | 5-HT agonist 8-hydroxy-2-(di-n-propylamino) tetralin |
| 8-OH-DPAT | 5-HT(1A) receptor agonist, 8-hydroxy 2(di-n-propyl(amino)tetralin |
| (35)S | Agonist-stimulated |
| GNRH-a | GnRH agonist |
beta-arrestin
| agonist | 1. <anatomy> A prime mover. 2. <pharmacology> A drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances, thus triggering a biochemical response. (18 Nov 1997) |
|---|---|
| calcium channel agonist | <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (12 Dec 1998) |
| receptor agonist | A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted. (22 May 1997) |
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
| muscarinic agonist | Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (12 Dec 1998) |
| histamine agonist | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (12 Dec 1998) |
| opioid agonist | <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression. (16 Dec 1997) |
| opioid partial agonist | <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response. (16 Dec 1997) |
| LH and RH agonist | <pharmacology> Particular medications that act as potent inhibitors of gonadotrophin (testosterone) secretion. They act to inhibit the production of testosterone through a feedback mechanism on the pituitary gland. LH and RH agonists are useful in the treatment of prostate cancer. (14 Oct 1997) |
| androst-5-ene-3 beta,17 beta-diol | <chemical> An adrenal-derived oestrogenic metabolite of dhea. Evidence exist for its use as an endocrine regulator of immune response. Pharmacological action: anabolic steroids. Chemical name: Androst-5-ene-3,17-diol, (3beta,17beta)- (12 Dec 1998) |
| beta-1,3-galactosyl-0-glycosyl-glycoprotein beta-1,3-N-acetylglucosaminyltransferase | <enzyme> Capable of adding a glcnac residue to g1cnacman(3)g1cnac; from mung bean seedlings Registry number: EC 2.4.1.146 Synonym: n-acetylglucosaminyltransferase II, gal3-(glcnac6)galnac-mucin (glcnac--gal)3-glcnactransferase (26 Jun 1999) |
| beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferase | <enzyme> With EC 2.4.1.148 this is called beta6-glcnac-transferase b Registry number: EC 2.4.1.102 Synonym: gal3-galnac-mucin-6-glcnac transferase, udp-glcnac-gal1-3galnac-r-(glcnac to galnac)-beta1-6glcnac transferase, core 2 glcnac transferase, core 2-n-acetylglucosaminyltransferase, core 2 beta6-gn-t (26 Jun 1999) |
| beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase | <enzyme> Induced in preneoplastic stage of liver carcinogenesis promoted by orotic acid in rats; adds "bisecting n-acetylglucosaminyl residue in beta 1,4 linkage to the beta-linked mannose of the core of asparagine-linked oligosaccharides Registry number: EC 2.4.1.144 Synonym: n-acetylglucosaminyltransferase III, udpgnac-glycopeptide beta4-n-acetylglucosaminyl transferase III, udpgnac-magtransferase III, udp-n-acetylglucosamine-beta-d-mannoside beta-1,4-n-acetylglucosaminyltransferase III (26 Jun 1999) |
| beta-hydroxy-beta-methylglutaryl-CoA | -OOCCH2C(OH)(CH3)CH2COS-CoA;a key intermediate in the synthesis of ketone bodies and of steroids. Synonym: 3-hydroxy-3-methylglutaryl-CoA. Beta-hydroxy-beta-methylglutaryl-lyase, an enzyme, found primarily in liver and rumen epithelium that catalyses the formation of acetyl-CoA and acetoacetate from beta-hydroxy-beta-methylglutaryl-CoA; a key step in ketogenesis; a deficiency of this enzyme leads to episodes of severe metabolic acidosis without ketosis. Beta-hydroxy-beta-methylglutaryl-reductase, an enzyme that catalyses the rate-limiting step of cholesterol biosynthesis, beta-hydroxy-beta-methylglutaryl-CoA + 2NADPH + 2H+ → mevalonate + 2NADP+ + coenzyme A. Beta-hydroxy-beta-methylglutaryl-synthase, an enzyme in mitochondria that catalyses the reaction of acetyl-CoA with acetoacetyl-CoA and water to form beta-hydroxy-beta-methylglutaryl-CoA and coenzyme A, a step required for both ketogenesis and steroidogenesis to occur. (05 Mar 2000) |
| beta-n-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase | <enzyme> An enzyme that catalyses the transfer of galactose from udp-galactose to a specific glycoprotein receptor, 2-acetamido-2-deoxy-d-glucosyl-glycopeptide, during glycopeptide synthesis. Chemical name: UDPgalactose:N-acetyl-beta-D-glucosaminylglycopeptide beta-1,4-galactosyltransferase Registry number: EC 2.4.1.38 (12 Dec 1998) |
| beta agonist |
A drug that stimulates adrenergic receptors in the lungs, heart, uterus, and other organs. Beta agonists are used to treat asthma and chronic obstructive lung diseases and to manage pregnancy.
출처:
|
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|